Video Home Visits for Dietary Counselling

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Nov 12, 2020

Keywords

ClinConnect Summary

This clinical trial, titled "Video Home Visits for Dietary Counselling," is designed to see if virtual visits can help people who have a history of calcium-based kidney stones reduce their sodium intake. The study will explore what information is most useful during these video visits and compare the results to traditional dietary counseling. The main goal is to help participants lower their sodium levels, which may help prevent future kidney stone issues.

To be eligible for this study, participants should be at least 18 years old and have a history of calcium-based kidney stones, confirmed through tests. They also need to have access to a smartphone, tablet, or computer that can support video calls. During the trial, participants will take part in home video visits where they will receive dietary advice tailored to help them manage their sodium intake. It’s important to note that this study is not yet recruiting, so interested individuals will need to wait until it officially starts.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients known to have a history of calcium-based kidney stone disease verified by stone analysis (stones containing calcium oxalate(CaOx) or calcium phosphate(CaP) on stone analysis), or patients with a diagnosis of kidney stone disease verified by imaging (computerized tomography, ultrasound, or plain film/x-ray) and a prior 24-hour urine results with elevated SS CaOx\>8 or SS CaP\>1.25.
• • Patients 18 years or older.
• • Patients with a smartphone, internet capable tablet, or video capable laptop.
• • Patients with a household member with a smartphone, internet capable tablet, or video capable laptop.
• Exclusion Criteria:
• • Pregnant patients.
• • Patients unable to produce a urine sample.
• • Patients who have previous surgical reconstruction involving incorporation of bowel in the urinary tract.
• • Patients with known sodium regulation abnormalities (adrenal tumors, pituitary tumors, glucocorticoid deficiency, hypothyroidism, syndrome of inappropriate antidiuretic hormone secretion, nephrotic syndrome, severe congestive heart failure, severe hepatic impairment, etc.).
• • Patients on medications significantly affecting urinary sodium levels (lithium, amphotericin, vasopressin V2-receptor antagonists, lactulose, for example).